Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202735 | 0.91 | AR (0.36) | MAPTALDH1A1KDM4ELMNAAR | |
| SCHEMBL202935 | 0.89 | AR (0.35) | MAPTALDH1A1ARCTNNB1TCF7L2 | |
| SCHEMBL203001 | 0.88 | MRGPRX4 (0.34) | MAPTALDH1A1PTGDR2LMNAAR | |
| SCHEMBL203660 | 0.88 | NR1H2 (0.32) | MAPTALDH1A1GAALMNAADORA3 | |
| SCHEMBL205068 | 0.88 | PTGER4 (0.35) | MAPTALDH1A1KDM4EPTGER4AR | |
| SCHEMBL203687 | 0.88 | AR (0.36) | AR | |
| SCHEMBL203698 | 0.88 | AR (0.35) | MAPTLMNAAR | |
| SCHEMBL205795 | 0.86 | DUSP3 (0.38) | MAPTKDM4ETP53PTGER4AR | |
| SCHEMBL204445 | 0.85 | AR (0.35) | MAPTPTGER4ARADORA3 | |
| SCHEMBL203234 | 0.85 | MRGPRX4 (0.32) | MAPTALDH1A1PTGDR2ARADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3428148-B1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3498696-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARASITICIDAL COMPOUNDS | Merial, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-3428148-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | Merial, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-3050874-B1 | ENANTIOMERIALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | MERIAL INC (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-3088384-B1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL INC (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2010056999-A9 | ENANTIOMERICALLY ENRICHED ARYLOAZOL- 2 -YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | MERIAL LIMITED (US) | 2018-06-07 | — | — | WO | disclosed |
| EP-3088384-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | Merial, Inc. (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2155699-B9 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-3050874-A1 | ENANTIOMERIALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | Merial, Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2639228-B1 | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof | MERIAL INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20140080862-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | AVENTIS AGRICULTURE (FR) | 2014-03-20 | — | — | US | disclosed |
| EP-2639228-A2 | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof | Merial Limited (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8461176-B2 | Enantiomerically enriched aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof | MERIAL LIMITED (US) | 2013-06-11 | — | — | US | disclosed |
| US-8283475-B2 | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof | MERIAL LIMITED (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120149750-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8088801-B2 | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof | MERIAL LIMITED (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100125089-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2010-05-20 | — | — | US | disclosed |
| EP-2155699-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | Merial Limited (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20080312272-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2008144275-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149750-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4X1, CBR3, TYR | MAPT 4740/4885ALDH1A1 1677/4885KDM4E 77/4885 |
| US-20080312272-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4X1, CBR3, TYR | MAPT 4740/4885ALDH1A1 1677/4885KDM4E 77/4885 |
| US-20100125089-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4B1, NPY4R, CYP4X1 | MAPT 4779/4885ALDH1A1 1144/4885KDM4E 38/4885 |
| US-20140080862-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4X1, CBR3, TYR | MAPT 4740/4885ALDH1A1 1677/4885KDM4E 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.